Hutchmed Reports the US FDA's Acceptance of Surufatinib's NDA for Advanced Neuroendocrine Tumors
Shots:
- The NDA is based on two P-III studies of surufatinib in patients with pancreatic and extra-pancreatic NET in China. The anticipated PDUFA date is April 30- 2022
- The same data from the studies will be used to file MAA to the EMA imminently- based on scientific advice from the EMA’s Committee for Medicinal Products for Human Use
- Surufatinib received FTD in Apr’20 and ODD in Nov’19 for the treatment of pancreatic and extra-pancreatic NET. Hutchmed currently retains all rights to surufatinib globally
| Ref: Hutchmed | Image: Hutchmed
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com